The enrichment of putative CD44+/CD24-/low breast stem cell populations following exposure to ionizing radiation (IR) has been ascribed to their inherent radioresistance and an elevated frequency of symmetric division during repopulation. However,recent studies demonstrating radiation-induced phenotypic reprogramming (the transition of non-CD44+/CD24-/low cells into the CD44+/CD24-/low phenotype) as a potential mechanism of CD44+/CD24-/low cell enrichment have raised the question of whether a higher survival and increased self-renewal of existing CD44+/CD24-/low cells or induced reprogramming is an additional mode of enrichment. To investigate this question, we combined a cellular automata model with in vitro experimental data using both MCF-10A non-tumorigenic human mammary epithelial cells and MCF-7 breast cancer cells, with the goal of identifying the mechanistic basis of CD44+/CD24-/low stem cell enrichment in the context of radiation-induced cellular senescence. Quantitative modeling revealed that incomplete phenotypic reprogramming of pre-senescent non-stem cells (reprogramming whereby the CD44+/CD24-/low phenotype is conveyed, along with the short-term proliferation capacity of the original cell) could be an additional mode of enriching the CD44+/CD24-/low subpopulation. Furthermore, stem cell enrichment in MCF-7 cells occurs both at lower doses and earlier time points, and has longer persistence, than that observed in MCF-10A cells, suggesting that phenotypic plasticity appears to be less regulated in breast cancer cells. Taken together, these results suggest that reprogramming of pre-senescent non-stem cells may play a significant role in both cancer and non-tumorigenic mammary epithelial populations following exposure to IR, a finding with important implications for both radiation therapy and radiation carcinogenesis.
CITATION STYLE
Gao, X., Sishc, B. J., Nelson, C. B., Hahnfeldt, P., Bailey, S. M., & Hlatky, L. (2016). Radiation-induced reprogramming of pre-senescent mammary epithelial cells enriches putative CD44+/CD24-/low stem cell phenotype. Frontiers in Oncology, 6(JUN). https://doi.org/10.3389/fonc.2016.00138
Mendeley helps you to discover research relevant for your work.